Omeros Co. (NASDAQ:OMER) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company cut its holdings in shares of Omeros Co. (NASDAQ:OMER) by 10.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,433 shares of the biopharmaceutical company’s stock after selling 2,705 shares during the period. The Manufacturers Life Insurance Company’s holdings in Omeros were worth $91,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. acquired a new stake in shares of Omeros during the 1st quarter valued at $85,000. AQR Capital Management LLC purchased a new position in Omeros during the 2nd quarter worth approximately $105,000. Comerica Bank grew its position in Omeros by 20.0% during the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 5,000 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Omeros by 75.5% during the 1st quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 12,951 shares during the period. Finally, Cypress Capital Group boosted its position in shares of Omeros by 40.0% in the second quarter. Cypress Capital Group now owns 35,000 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 10,000 shares during the period. 48.79% of the stock is currently owned by institutional investors.

Omeros Stock Performance

Omeros stock opened at $4.15 on Monday. The firm’s 50 day moving average price is $3.98 and its two-hundred day moving average price is $3.94. The firm has a market cap of $240.49 million, a PE ratio of -1.77 and a beta of 1.48. Omeros Co. has a twelve month low of $1.05 and a twelve month high of $5.68.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($1.12) earnings per share for the quarter. Equities analysts anticipate that Omeros Co. will post -2.9 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research report on Friday, August 16th.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.